Latest Breaking News On - Infantile malignant osteopetrosis - Page 1 : comparemela.com
Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501
cadillacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cadillacnews.com Daily Mail and Mail on Sunday newspapers.
Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Posted on 344
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial and operational results for the fourth quarter and year ended December 31, as well as guidance for anticipated 2021 milestones.
“2021 is poised to be another exciting year for Rocket,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket. “We anticipate clinical data from all five of our gene therapy programs, initiation of our first in-house AAV cGMP production from our new manufacturing facility, and continued strengthening of our organization, manufacturing capabilities and infrastructure. We look forward to continued validation of our gene therapy platforms with updated results from registrational studies in FA and LAD-I, longer term findings in Danon Disease and PKD, and clinical proof-of-concept for
Biotech Stock Picks That Delivered Triple-digit Gains - Is There More Room To Run?
NEW YORK CITY (dpa-AFX) - As 2020 draws to a close, it s time to take a look at the top performing healthcare stocks that we profiled this year. Of the 53 stocks to which our premium subscribers have been alerted, 18 stocks have posted triple-digit gains.
What are the catalysts driving these stocks? Is there more room to run? Let s walk you through the details.
1. DermTech Inc. (DMTK)
DermTech, a commercial-stage genomics company in dermatology, was trading around $11, when we alerted our premium subscribers to it on January 19, 2020. The stock touched a high of $27.42 in intraday trading yesterday and that represents a gain of 136% from our published price.